Revelation Biosciences, Inc. (REVB), a clinical-stage life science company, reported a net loss of $8.91 million for the year ended December 31, 2025, compared to a net loss of $15.04 million for the previous year. The company's revenue remains at $0 as it has no products approved for commercial sale. The decrease in net loss was primarily due to a $7.22 million increase in other income, partially offset by a $1.10 million increase in operating expenses.
Research and development expenses increased to $4.06 million in 2025 from $3.55 million in 2024, driven by higher clinical study expenses for GEM-AKI and GEM-CKD and increased personnel costs. General and administrative expenses also rose to $5.01 million from $4.43 million, mainly due to higher legal and professional fees. As of December 31, 2025, Revelation Biosciences had cash and cash equivalents of $10.70 million, a significant increase from $6.50 million at the end of 2024.
Key operational developments included meeting with the FDA and obtaining agreement on a single Phase 2/3 adaptive design study for GEM-AKI. The company plans to build the necessary infrastructure to run this clinical study, including engaging a scientific advisory board and a clinical research organization. Revelation Biosciences also intends to conduct preclinical toxicology studies to support a repeat dose Phase 2 study for GEM-CKD. As of February 23, 2026, the company had 8 full-time employees and one part-time employee, with 5 engaged in research and development and 4 in general and administrative activities.
The company's financial statements include a going concern qualification, as its current cash and cash equivalents are not expected to be sufficient to sustain operations within one year after the issuance of the audited financial statements for December 31, 2025. To address this, Revelation Biosciences plans to seek additional funding through public or private equity or debt financings. Subsequent to the reporting period, on January 23, 2026, the company entered into a warrant inducement transaction, receiving net proceeds of approximately $6.7 million. The company also effected a 1-for-4 reverse stock split on January 28, 2026, to maintain its Nasdaq listing.
About REVELATION BIOSCIENCES, INC.
Revelation Biosciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies based on its proprietary Gemini platform. Its programs target conditions such as acute kidney injury, chronic kidney disease, and post-surgical infections by harnessing innate immune response modulation. The company focuses on innovative, inflammation-rebalancing treatments, relying on strategic partnerships, licensing agreements, and third-party manufacturing to advance its pipeline toward regulatory approval and commercialization.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.